AstraZeneca Looks To Muscle In On BMS-Dominated Neoadjuvant NSCLC Setting

Although AstraZeneca PLC wasn’t one of the first PD-1/LI sponsors to make it to market, new Phase III data may position the company’s Imfinzi (durvalumab) to be an early entrant for neoadjuvant treatment of non-small cell lung cancer (NSCLC), a space where Bristol Myers Squibb Company’s PD-1 inhibitor Opdivo (nivolumab) had the distinction of winning US Food and Drug Administration approval earlier this year and where other PD-1/L1 players are hoping to compete as well. 

The British drug maker is busy at work making Imfinzi a player in earlier lines of treatment, such as neoadjuvant as well as adjuvant treatment of solid tumors, which is...